Maine BioTek Inc Profile last edited on: 2/27/18
CAGE: 3CQQ4
UEI:
Business Identifier: NO Business Identifier is currently available for this company. 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
259 Main Street PO Box 408
Winterport, ME 04496
Winterport, ME 04496
| (207) 223-4662 |
| sclouthier@hotmail.com |
| www.mainebiotek.com |
Location: Single
Congr. District: 02
County: Waldo
Congr. District: 02
County: Waldo
Public Profile
Maine Biotek is focused to issues in fish pathology and in their quest for relevant vaccines to address diseases, principals of the firm are working their way through dozens of potential approaches. Once vaccines seems to have potential in the lab, Anderson and Clouthier continue their work at a Canadian government research facility in St. Andrews, New Brunswick. The first few BioTek vaccines to receive approval probably will be produced at an out-of-state facility, but, the hope is to build the sort of sanitary facility needed for vaccine production - both for ISA and a number of other fish diseases that the company is investigating -in Maine
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
1-4Revenue Range
Less than .5MVC funded?
NoPublic/Private
Privately HeldStock Info
----IP Holdings
N/AAwards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2007 | 2 | NSF | $599,322 | |
| Project Title: Atlantic Cod Nodavirus Vaccine | ||||
| 2007 | 2 | DOC | $395,000 | |
| Project Title: A Multivalent Bacterial Vaccine for Atlantic Cod | ||||
| 2005 | 2 | USDA | $371,000 | |
| Project Title: Preparation of an IHN Virus Whole Killed Vaccine: Retention of Neutralizing Epitope Integrity of the IHN Virus Glycoprotein During Viral | ||||
| 2004 | 2 | USDA | $371,000 | |
| Project Title: Recombinant ISA Virus Vaccine | ||||
| 2003 | 1 | NSF | $94,376 | |
| Project Title: Recombinant Infectious Hematopoietic Necrosis (IHN ) Virus G Protein Vaccine | ||||
Key People / Management
Sharon Clouthier -- President
Eric Anderson
Eric Anderson
Company News
There are no news available.
